" class="no-js "lang="en-US"> Rengaraj Venkatesh - Medtech Alert
Monday, September 15, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Rengaraj Venkatesh

Rengaraj Venkatesh

About Rengaraj Venkatesh

Dr. Venkatesh began his career as Medical officer in General Ophthalmology department at Aravind eye hospital, Madurai and later moved to Glaucoma department. At present he is the Chief Medical Officer of Aravind Eye Hospital, Pondicherry.

Dr. Venkatesh graduated in medicine with a gold medal in Ophthalmology from Annamalai University and DO & D.N.B from Aravind Eye Hospital, Madurai. In 2000, he completed Basic and clinical science assessment from International council of Ophthalmology.

Related Story

Artificial Intelligence

 Remidio's Medios AI Shows Significant Promise in Last-mile Screening for Referable Glaucoma | Pharmtech Focus

Remidio's Medios AI Shows Significant Promise in Last-mile Screening for Referable Glaucoma

July 8 2022

Glaucoma, one of the world’s leading causes of irreversible blindness, is expected to affect an […]